Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that it entered into an exclusive license agreement with Ferring Pharmaceuticals (“Ferring”), a research-driven, specialty biopharmaceutical group, for the marketed product NOCDURNA ® (desmopressin acetate), which is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate,
October 1, 2020
· 6 min read